Levosimendan is an intravenous inodilator drug used to treat acutely decompensated severe chronic heart failure by enhancing cardiac contractility and inducing vasodilation.
Marketed as Simdax.
It works as a calcium sensitizer to strengthen heartbeats without increasing oxygen demand and opens potassium channels to decrease cardiac workload.
Calcium Sensitization: Binds to cardiac troponin C, improving muscle contraction without raising intercellular calcium levels.
Vasodilation: Opens adenosine triphosphate (ATP)-sensitive potassium channels in vascular smooth muscle, decreasing preload and afterload.
Cardioprotection: Known for anti-stunning and anti-ischemic effects.
Indicated Medical Conditions Treated:
Acutely Decompensated Heart Failure: Severe chronic failure. Cardiac Surgery: Used to improve post-operative cardiac function. Shock Management: Utilized in cardiogenic and septic shock. Other conditions: Takotsubo cardiomyopathy and right ventricular failure.
Side Effects and Safety Levosimendan is generally well-tolerated, but the most common side effects include:
Hypotension (low blood pressure) Headache Atrial fibrillation Hypokalemia Tachycardia
Key Details Administration: Intravenous (IV) infusion. Approval Status: Approved for use in many countries, but not currently approved by the FDA in the United States.